Barriers to Global Recognition of Traditional African Medicines: A Systematic Review of Cultural, Scientific, Regulatory, and Economic Factors

Despite the profound cultural and medicinal heritage of traditional African medicines (TAM), their global recognition remains notably limited. This study investigates the factors behind this issue, focusing on cultural perceptions, scientific validation, regulatory frameworks, and pharmaceutical industry influence. Utilizing a systematic literature review (SLR) to provide a thorough and structured overview, the research addresses these factors with transparency and reproducibility. Key findings reveal that negative cultural perceptions, the dominance of Western medicine, and skepticism towards traditional healers, especially in urban and educated populations, marginalize TAM. Additionally, religious beliefs and historical influences, such as colonialism, further devalue indigenous knowledge systems. The study also highlights a significant lack of scientific research and clinical trials, which challenges the conventional validation of TAM’s efficacy. Moreover, inconsistent international and national regulatory frameworks and the pharmaceutical industry’s dominance impede TAM’s integration into global healthcare systems. To enhance TAM’s credibility and global acceptance, the study advocates for standardized regulatory policies, increased scientific research, and a reevaluation of intellectual property laws. This shift towards a more inclusive and integrative approach in global health systems could bridge the gap between traditional and modern medical practices, promoting a more holistic understanding of health and wellness.

The Development and Experience of American Pharmaceutical Industry Associations and Its Enlightenment to China

Objective To study the development history and current situation of pharmaceutical industry associations in the United State and to provide reference for China’s pharmaceutical industry associations.Methods Literature research and comparative study were used to investigate the development history and current situation of pharmaceutical associations in the United States.Then,their characteristics and experiences were summarized.Some countermeasures and suggestions were put forward for the existing problems of pharmaceutical associations in China.Results and Conclusion The institutional environment of pharmaceutical associations in the United States is relatively good,reflecting the characteristics of emphasizing process management and neglecting entrance management with and the help of public supervision.At the same time,the government advocates market competition by adhering to the market-oriented services for the public.American pharmaceutical industry associations have strong innovation capacity and perfect credit system.Drawing on the experience of pharmaceutical industry associations in the United States,China should strengthen the construction of pharmaceutical industry associations.Firstly,the supervision mechanism should be improved.Secondly,these associations should have good partnerships with the government and offer the public the best services.Finally,the fund-raising mechanism of pharmaceutical industry associations should be optimized to ensure the innovative development of the pharmaceutical industry.

Research on the Threshold Effect of China’s Pharmaceutical Export Trade on Internal and External R&D Investment

Objective To study the threshold effect of export trade on internal and external R&D investment in China’s pharmaceutical industry,and to provide reference for some pharmaceutical enterprises to improve the investment.Methods The panel data of pharmaceutical industry in 25 provinces and cities in China from 2009 to 2019 were selected to conduct empirical analysis by establishing a threshold regression model,and a better export trade interval was obtained.Results and Conclusion There is a threshold value for the effect of new product export on both internal and external R&D expenditures,and the threshold values are 845.2788 million yuan and 318.4198 million yuan,respectively.There is a single threshold effect of export trade on both internal and external R&D investment in China’s pharmaceutical industry,and the effect of export trade on internal and external R&D investment changes from negative to positive as the export trade develops from low to high.

Countermeasures and Suggestions for Strengthening Human Resource Management in China’s Pharmaceutical Industry

Objective To provide reference and enlightenment for the development of human resource management in China’s pharmaceutical industry and to put forward some suggestions to promote the further development of pharmaceutical industry.Methods The method of literature review was used to analyze the current situation and existing problems of human resource management in China’s pharmaceutical industry.Results and Conclusion Only by continuously improving the human resource management skills and innovating management methods can pharmaceutical enterprises achieve long-term benefits with sustainable development.The formulation of human resource management strategy in pharmaceutical industry must be conducive to the realization of the business goals of enterprises.To achieve this overall goal,the human resources management department of enterprises must make the plan from a strategic perspective,formulate talent strategic planning which serves the overall strategic goal of the enterprise.As a result,human resource management will play an important role in the development of China’s pharmaceutical industry.

Rethinking counterfeit medical supply chains:A critical review of the current literature

The medical device and pharmaceutical industries include a range of drugs,machines,instruments,and apparatuses used to prevent,diagnose,treat disease and illness,or aid in rehabilitation for patients,and are expected to grow substantially in the coming years.However,they are often targets of criminal organizations who manufacture and profit from fraudulent products,infiltrating the market with counterfeit medical supply chains.In this paper,we discuss and analyze the extent and nature of this problem and make suggestions for mitigation and prevention of this worldwide challenge.Ultimately,we argue that a holistic approach is essential to addressing this problem,including the creation and dissemination of reliable and good quality data,developing healthcare systems to be more robust,establishing/enhancing intra‐and international cooperation around this issue,and employing effective technological solutions,such as digital tracing.

Research on the Influence of Government R&D Funding and Enterprise R&D Investment on the Innovation Efficiency of Pharmaceutical Industry

Objective To study the effect of government R&D funding and enterprise R&D input on innovation efficiency of China’s pharmaceutical industry.Methods Based on the inter-provincial panel data of China’s pharmaceutical industry from 2009 to 2019,the stochastic frontier analysis method was used to study the influence of government R&D funding and enterprise R&D input on the innovation efficiency.Results and Conclusion With 1%increase in government R&D funding,the innovation efficiency of enterprises will increase by 0.122%.When R&D investment increases by 1%,innovation efficiency will increase by 0.169%.Both government R&D funding and enterprise R&D investment promote the innovation efficiency of pharmaceutical enterprises,but the increase of enterprise R&D investment contributes more to the improvement of pharmaceutical innovation efficiency.

The Potential of Industrial Agglomeration to Promote Pharmaceutical Innovation: Analysis of China's “Medicine Valley” Construction Upsurge

This paper reports the innovation effect of pharmaceutical industry agglomeration from the perspective of patterns of agglomeration and innovation,by using registration application data for innovative and generic drugs as indicators of pharmaceutical innovation.First,the distribution of the pharmaceutical industry in China is characterized by high agglomeration and low innovation.Second,no significant infuence is exerted by regional industrial and development zone agglomeration on the development of innovative drugs in different regions;the effect of the promotion of generic drugs is reflected mainly in the location entropy index.Third,the existence of a crowding effect weakens the effect of the promotion of agglomeration on pharmaceutical innovation and the adverse impact on innovative drugs is significantly greater than the effect on generic drugs.In further research,we explored the bias effect of agglomeration in development zones and the synergistic effects of different agglomeration models.It is difficult to improve the quality of independent innovation by spatial agglomeration.Government-led development zones play a rather limited role in pharmaceutical innovation.

上海药物研发行业职业健康管理现状与改进策略

目的 了解上海药物研发行业职业健康管理现状及面临的挑战,为制订行业职业健康管理策略,促进行业健康发展提供参考。方法 采用问卷调查法对上海48家药物研发公司的职业健康风险、管理现状及存在的问题进行梳理,采用现场调研法对5家代表性公司实地了解行业职业危害防护和新业态的管理需求,探讨可行的解决方案。结果 问卷调查结果显示半数以上的药物研发公司从事小分子药物和抗肿瘤药物研发,面临着研发试剂、研发中的药物、病原微生物和实验动物等多重健康风险。职业病防护设施“三同时”工作完成率为43.8%,职业病危害因素检测和职业健康监护的开展率分别为89.6%和79.2%。现场调研发现药物研发行业的建筑通风、职业危害防护以及新业态的职业健康管理面临挑战。结论 随着药物研发行业的快速发展,潜在职业健康风险不容忽视,职业危害防护和管理工作亟待细化和完善。

Leveraging Blockchain with Optimal Deep Learning-Based Drug Supply Chain Management for Pharmaceutical Industries

Due to its complexity and involvement of numerous stakeholders,the pharmaceutical supply chain presents many challenges that companies must overcome to deliver necessary medications to patients efficiently.The pharmaceutical supply chain poses different challenging issues,encompasses supply chain visibility,cold-chain shipping,drug counterfeiting,and rising prescription drug prices,which can considerably surge out-of-pocket patient costs.Blockchain(BC)offers the technical base for such a scheme,as it could track legitimate drugs and avoid fake circulation.The designers presented the procedure of BC with fabric for creating a secured drug supplychain management(DSCM)method.With this motivation,the study presents a new blockchain with optimal deep learning-enabled DSCM and recommendation scheme(BCODL-DSCMRS)for Pharmaceutical Industries.Firstly,Hyperledger fabric is used for DSC management,enabling effective tracking processes in the smart pharmaceutical industry.In addition,a hybrid deep belief network(HDBN)model is used to suggest the best or top-rated medicines to healthcare providers and consumers.The spotted hyena optimizer(SHO)algorithm is used to optimize the performance of the HDBN model.The design of the HSO algorithm for tuning the HDBN model demonstrates the novelty of the work.The presented model is tested on the UCI repository’s open-access drug reviews database.

Research on the Relationship between Export Orientation and R&D Investment of China’s Pharmaceutical Industry in Different Regions

Objective To study the relationship between export orientation and research and development(R&D)investment so as to provide suggestions and references for improving the R&D investment level and innovation capabilities of pharmaceutical industry due to the progress of globalization and the continuous development of export trade of China’s pharmaceutical industry.Methods The relevant data of China’s pharmaceutical industry from 2001 to 2016 was selected to establish an error correction model based on the co-integration theory,and then the Granger causality test was conducted to determine the relationship between the export orientation and R&D investment of China’s pharmaceutical industry in different regions.Results and Conclusion It is found that the export orientation of the pharmaceutical industry in different regions has a significant negative impact on the investment of R&D.Among them,the middle region has the greatest impact,followed by the eastern and western regions.The export orientation of the pharmaceutical industry in the middle region has a lag effect on R&D investment,and the lag phase is two years.

Gauging a Firm's Innovative Performance Using an Integrated Structural Index for Patents

Purpose： In this contribution we try to find new indicators to measure characteristics of a finn＇s patents and their influence on a company＇s profits. Design/methodology/approach： We realize that patentevaluation and influence on a company＇s profits is a complicated issue requiring different perspectives. For this reason we design two types of structural h-indices, derived from the International Patent Classification （IPC）. In a case study we apply not only basic statistics but also a nested case-control methodology. Findings： The resulting indicator values based on a large dataset （19,080 patents in total） from the pharmaceutical industry show that the new structural indices are significantly correlated with a firm＇s profits. Research limitations： The new structural index and the synthetic structural index have just been applied in one case study in the pharmaceutical industry. Practical implications： Our study suggests useful implications for patentometric studies and leads to suggestions for different sized firms to include a healthy research and development （R＆D） policy management. The structural h-index can be used to gauge the profits resulting from the innovative performance of a firm＇s patent portfolio. Originality/value： Traditionally, the breadth and depth of patents of a firm and their citations are considered separately. This approach, however, does not provide an integrated insight in the major characteristics of a firm＇s patents. The Sh（Y） index, proposed in our investigation, can reflect a firm＇s innovation activities, its technological breadth, and its influence in an integrated way.

Developments in the Pharmaceuticals Industry

China’s pharmaceuticals industry is one of the industries making use of foreign funds and running three kinds of foreign-funded enterprises from an early date. In 1980, it signed a contract with the Japanese Pharmaceu-tical Enterprise to establish the China Otsuka Pharmaceuticals Co. Ltd.---the first joint venture in China’s pharma-ceuticals industry. According to incom-

Board Effectiveness in Pharmaceutical Industry： The Case of TAPIC Pharmaceutical Group

Pharmaceutical industry plays a strategic role in economy of Iran. Corporate governance, in pharmaceutical companies as the very core of an organization, and the driving force of corporate leadership, plays a significant role in business success and overall productivity of the firms. As yet, the characteristics, factors causing success and failure of core governance in Iranian pharmaceutical industry have remained unsearched. Furthermore, the applicability of western theories and models to the traditional societies such as Iran are largely unknown. This study is an attempt to explore the pattern of board effectiveness and firm performance in Iranian pharmaceutical industry and suggesting an alternative good governance model suitable to apply to less developed countries （LDC） pharmaceutical industry, with emphasis on Iranian context. After An intensive literature review the model suggested by Ingley and Van der Walt （2001） was found to be more comprehensive, practical and suitable for this study. However, after empirical evaluation further development to the model to fit the pharmaceutical industry and the context of LDCs, especially Iran, is suggested. Empirically the paper stands upon a rich database consisting of Tamin Active Pharmaceutical Ingredients Investment Company （TAPIC） and its 11 subsidiary companies which are treated as 11 mini-cases. Data were collected by document analysis, questionnaire and interviews. Since two of the authors have many years experience as managers in the same industrial group, we got access to rich information that normally are not accessible to researchers in less developed countries. The results suggest some improvements to the earlier models and show that the pattern of board effectiveness in Iranian pharmaceutical industry can be influenced by： （1） Internal factors including： （a） board members, the personality and background, （b） board composition, which is influenced by selection criteria, Tribalism, interpersonal relationship and belonging to the same ideological group, （c） board interactions, and （d） power distribution in the board, which is influenced by parenting power in holding companies. All internal factors are directly or indirectly affected by political issues as well as socio-cultural forces. （2） External factors including： （a） industrial complexity and the nature of industry, （b） industrial ethos, （c） legislation, and political forces, （d） economy, which the last two factors are influenced by international environment as well.

PROSPECTS OF CHINA'S PHARMACEUTICAL INDUSTRY

Director-general of the StateAdministration of Medicines ZhengXiaoyu gave an interview recently onthe development of China’s medicines in the9th Five-Year Plan period(1996-2000) andthe long-term development programme upto 2010.

Optimization of a Method for the Simultaneous Determination of Phloroglucinol and Trimethylphloroglucinol by High Performance Liquid Chromatography in Routine Use in a Pharmaceutical Industry in Abidjan

In order to provide the population with safe, effective and good quality medicines, the pharmaceutical industries, before releasing batches of their products into the pharmaceutical circuit, put in place internal dosage methods to control the quality of these products. The present study consisted in optimizing a method for the simultaneous determination of Phloroglucinol (PHG) and Trimethylphloroglucinol (TPH) by high performance liquid chromatography (HPLC) routinely used in a pharmaceutical industry located in a township in Abidjan (Ivory Coast). The basic chromatographic conditions were those routinely used for the determination of these two molecules: mobile phase: acetonitrile/water (60/40), stationary phase (C18 BDS Hypersil 250 mm * 4.6 mm - 5 μm), detection wavelength (265 nm), flow rate, injection volume and run time configured at the equipment level were respectively 1 mL/min, 10 μL and 8 min. The method of preparation of the analytes (PHG and TPHG) was also applied by the pharmaceutical industry. The application of these different parameters at the equipment level made it possible to determine a chromatogram which highlights three chromatographic peaks with respective retention times (RT) of 0.773 min (unidentified compound), 2.275 min (PHG) and 7.269 min for an analysis time of 8 min with a better resolution of the peaks and baseline. The progressive optimization of different parameters such as the stationary phase (C18 YMC 150 mm * 4.6 mm - 3 μm), the proportion of the mobile phase: acetonitrile/water (80/20), the flow rate impelled by the pump (0.8 mL/min) and the modification of the analyte preparation mode (same amount of PHG and TPHG in a 50 mL volumetric flask) resulted in a final chromatogram that highlighted two chromatographic peaks at the respective RT of 2.391 min (PHG) and 3.735 min (TPHG) at a run time of 6 min. The chromatographic conditions that led to the final chromatogram can be used routinely by the pharmaceutical industry for the determination of several PHG and TPHG drug matrices after prior validation of the determination method.

Research on the Impact of Independent R&D and Collaborative Innovation on Economic Performance in China’s pharmaceutical Industry

Objective To study the impact of independent R&D and collaborative innovation on economic performance in the pharmaceutical industry.Methods A panel regression model was established by selecting the panel data of China’s pharmaceutical industry from 2009 to 2019.Results and Conclusion Independent R&D and collaborative innovation of the pharmaceutical industry in eastern,central and western regions of China had a positive effect on economic performance.Besides,the promotion effect of independent R&D was greater than that of collaborative innovation.The positive driving effect of economic performance is the largest among the three regions,followed by the central and western regions.The collaborative innovation has the greatest positive effect on economic performance in the central region,followed by the eastern and western regions.

Research on the Relationship between Cooperation Innovation Expenditure and Economic Output of China’s Pharmaceutical Industry

Objective To empirically analyze the relationship between cooperation innovation expenditure and economic output of China’s pharmaceutical industry,and provide a reference for improving its economic benefits and the capability of cooperation innovation in the future.Methods The relevant data of China’s pharmaceutical industry from 2000 to 2016 was selected as a sample.Based on the co-integration theory,an error correction model was established to conduct Granger test of causality to study the relationship between cooperation innovation expenditure and economic output of China’s pharmaceutical industry.Results and Conclusion The cooperation innovation expenditure of China’s pharmaceutical industry has a significant positive impact on economic output.If cooperation innovation expenditure increases 1%,its economic output will go up by 1.7%.At the same time,the long-term promotion effect of cooperation innovation expenditure on economic output is more significant than the short-term effect.

Comparative Study and Enlightenment on Innovation Achievements of Pharmaceutical Industry in Liaoning Province

Objective To promote the innovation and development of pharmaceutical industry in Liaoning Province.Methods Literature study and comparative study were used to investigate the current situation and problems of innovation-driven development of pharmaceutical industry in Liaoning Province by comparing data of Heilongjiang,Jilin,Shandong,and Jiangsu from four aspects of priority review and approval,consistency evaluation of generic drugs,new drugs on the market,and scientific and technological innovation achievements.Results and Conclusion In terms of innovation-driven development,pharmaceutical industry in Liaoning Province has the following problems,such as small scale,weak transformation of scientific and technological achievements,tough business environment,and single platform module of scientific and technological achievements.Combined with the actual development of pharmaceutical industry in Liaoning province,the government should give full play to its leading role and guide“Benxi Pharmaceutical Capital”to establish characteristic industrial cluster and incubation park.After high quality enterprises and high-level innovative talents get together,enterprises can analyze their actual situation to plan R&D layout,focusing on the input-output ratio.Meanwhile,the benign development of the enterprises,universities and research institutes should be promoted to integrate technical innovation and product supply.This can enhance the cooperation among the government,enterprise,university,and research institute,and provide reference for further development of pharmaceutical industry in Liaoning province.